Chicago Business
Chicago Business

AbbVie drops Alzheimer’s drug

AbbVie drops Alzheimer’s drug

Having trouble viewing this email? See the online version

Health Pulse Breaking News
Thursday, July 25, 2024
AbbVie

AbbVie drops development on Alzheimer’s drug

The beta antibody drug did not differentiate itself in clinical trials against already approved treatments manufactured by competitors.

 

Also: AbbVie sees higher profits as new drugs offset Humira decline
 
Read More >

Did someone forward this to you? Sign up for Health Pulse breaking news alerts here and unlock access to the full story with a Health Pulse subscription.

UNLOCK YOUR ACCESS

Discover the latest insights, analysis & opinion needed to navigate Chicago's complex business landscape.

<![if !mso]> <![endif]>
VIEW OUR SUBSCRIPTION OFFERS
 

This email was sent to chicagobusinessus627@emails.newslettersbase.com
Manage My Account | Contact Us
 

© 2024 Crain Communications Inc
130 E. Randolph St., Suite 3200, Chicago, IL 60601 United States
Privacy Policy | Terms and Conditions | Unsubscribe

 
  • This email was sent

    July 25, 2024 4:25pm

  • Country:

    United States

  • Tags
Prev Newsletter Next Newsletter